OTC · Drug Manufacturers - Specialty & Generic

Cipher Pharmaceuticals Inc. (CPHRF) Stock

$11.68 -0.17% OTC: CPHRF Healthcare

Cipher Pharmaceuticals Inc. functions as a specialized pharmaceutical company based in Canada.

Valuation

MetricValue
Price$11.68
Market Cap$296.57M
P/E Ratio9.56
P/B Ratio2.22
P/S Ratio5.82
EPS (TTM)$1.22
52-Week High$15.00
52-Week Low$8.64
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE25.69%
ROA20.19%
ROCE14.84%
Gross Margin74.53%
Operating Margin38.76%
Net Margin60.82%
Debt/Equity0.04
Current Ratio1.25

Annual Financials (USD)

Metric20212022202320242025
Revenue$22.0M$21.0M$21.0M$33.0M$51.0M
Operating Profit$12.0M$11.0M$12.0M$8.0M$17.0M
Net Profit$8.0M$27.0M$20.0M$12.0M$28.0M
EPS$0.29$0.99$0.80$0.46$1.07
Op Margin53.9%53.6%54.5%23.5%32.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$52.0M$74.0M$86.0M$163.0M$156.0M
Total Liabilities$13.0M$10.0M$6.0M$60.0M$30.0M
Cash$21.0M$29.0M$40.0M$18.0M$7.0M
Borrowings$1.0M$0$0$41.0M$5.0M

Latest News

Cipher Pharmaceuticals Inks LOI With pCPA to List Severe Acne Treatment Epuris MT Newswires · Jul 7, 2026 Cipher Pharmaceuticals and the pan-Canadian Pharmaceutical Alliance (pCPA) Sign Letter of Intent for Public Drug Plan Coverage of Epuris® CNW Group · Jul 6, 2026 Cipher Pharmaceuticals Announces Results of Annual General Meeting of Shareholders CNW Group · Jun 18, 2026 Why The Cipher Pharmaceuticals (TSX:CPH) Story Is Shifting As Analysts Lift Valuation Targets Simply Wall St. · May 23, 2026 Results: Cipher Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts Simply Wall St. · May 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$14.0M$11.0M$16.0M$20.0M$30.0M
Investing Cash Flow$0$0$0$-80.0M$0
Financing Cash Flow$-2.0M$-2.0M$-5.0M$0$-6.0M
Net Cash Flow$11.0M$8.0M$11.0M$-22.0M$-10.0M
Free Cash Flow$14.0M$10.0M$16.0M$20.0M$30.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.04
EV / EBITDA11.55
FCF Yield10.12%
Quick Ratio0.85
Interest Coverage39.01
Return 1Y28.07%
Return 3Y326.28%
Return 5Y791.60%

Ownership

Insiders Held42.36%
Institutions Held1.31%
Institutions Float Held2.27%
Institutional HolderSharesReport Date
Covestor Ltd3122022-12-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABTIAlterola Biotech, Inc. $0.00 — -0.11 $291900 0.00%
AONCAmerican Oncology Network, Inc. $12.00 +20.00% -17.39 $350.98M 0.00%
BHCCFBenchmark Holdings plc $0.37 +0.00% -4.13 $225.11M 0.00%
BHHKFCraftport Cannabis Corp. $0.00 — 0.00 $884 0.00%
HNSBFHansa Biopharma AB $2.90 +0.00% -4.72 $289.23M 0.00%

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals Inc. functions as a specialized pharmaceutical company based in Canada. The firm markets a diverse portfolio of therapies, including Epuris (CIP-ISOTRETINOIN), an isotretinoin formulation specifically developed for addressing severe acne; Ozenoxacin, prescribed for the management of impetigo in both adult and pediatric populations; Actikerall, indicated for treating palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream designed to diminish unwanted facial hair growth in women; BRINAVESS, a treatment aimed at restoring sinus rhythm in adults; and AGGRASTAT, an anti-platelet medication administered intravenously. Furthermore, Cipher holds licenses for several products, which encompass CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a fenofibrate-based formulation used to treat hyperlipidemia, a disorder characterized by high cholesterol; and Conzip/Durela (CIP-Tramadol), a tramadol formulation intended for alleviating moderate to moderately severe pain. Looking ahead, the company's development pipeline features several innovative compounds: Trevyent, a vasodilatory prostacyclin analogue targeting pulmonary arterial hypertension; CF-101, which is being explored for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical terbinafine formulation for the treatment of onychomycosis; and DTR-001, a cream under development for tattoo removal. Cipher Pharmaceuticals Inc. was established in the year 2000, with its primary operations located in Oakville, Canada.

Cipher Pharmaceuticals Inc. is headquartered in CA.

Cipher Pharmaceuticals Inc. (CPHRF) stock trades at $11.68 with a market capitalization of $296.57M. The stock is valued at a price-to-earnings (P/E) ratio of 9.56, price-to-book of 2.22, price-to-sales of 5.82. Over the past 52 weeks the stock has ranged between $8.64 and $15.00, and currently trades 22.1% below its 52-week high.

On profitability, Cipher Pharmaceuticals Inc. generates a return on equity (ROE) of 25.69% — well above the market average, a sign of a high-quality business, return on capital employed of 14.84%, an operating margin of 38.76%, a net profit margin of 60.82%.

Official website: www.cipherpharma.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides